Transmission of Antimicrobial Resistant Bacteria at the Hajj: A Scoping Review

Sara Alreeme 1,*, Hamid Bokhary 2 and Adam T. Craig 1

1 School of Population Health, Faculty of Medicine and Health, The University of New South Wales, Sydney 1466, Australia
2 University Medical Center, Umm Al-Qura University, Makkah 24243, Saudi Arabia
* Correspondence: saraalreeme@gmail.com

Abstract: Background: The Hajj is an annual religious mass gathering event held in Makkah, Saudi Arabia. With millions of participants from across the globe attending the Hajj, the risk of importation, transmission, and global spread of infectious diseases is high. The emergence of antimicrobial resistant (AMR) bacteria is of worldwide concern and the Hajj poses a serious risk to its dissemination. This review aims to synthesize published literature on AMR bacteria acquisition and transmission associated with the Hajj. Methods: We searched electronic databases to identify literature published between January 1990 and December 2021. The search strategy included medical subject headings and keyword terms related to AMR bacteria and the Hajj. Results: After screening 2214 search results, 51 studies were included in the analysis. The review found 6455 AMR bacteria transmissions related to the Hajj. Thirty predominantly enteric or respiratory disease-causing AMR bacterial species were reported with isolates identified in cases on five continents. Most were male, aged above 50 years and were diagnosed in Makkah. Most cases were identified through hospital-based research; few cases were detected in community or primary health care settings. Conclusions: This review provides a contemporary account of knowledge related to AMR transmission at the Hajj. It emphasizes the need for the enhancement of surveillance for AMR bacteria globally.

Keywords: Hajj; antimicrobial resistance; systematic review

1. Introduction

Antimicrobial resistance has emerged as a global threat to public health and health systems [1]. Antimicrobials are chemical compounds or drugs, including antibiotics, used therapeutically to stop the replication of disease-causing microorganisms in humans, animals, and plants [2]. Antimicrobial resistance (AMR) refers to a situation when microorganisms that would otherwise be susceptible to the antimicrobial agents undergo intrinsic changes over time that result in them developing an ability to survive (or resist) the effect of these agents [2]. AMR is accelerated by the over- and inappropriate use of antibiotics in agriculture and by humans [3].

Therapeutically, AMR has reduced the ability to effectively treat some disease-causing microorganisms, leading to increased mortality and morbidity [2]. This is perhaps most notably the case for Mycobacterium tuberculosis (TB), where around 29% of deaths among TB patients have been attributable to AMR TB [4]. Globally, the burden of disease associated with AMR in 2019 was estimated at 48 million disability-adjusted life years lost (DALYs), including 1.3-million deaths [5]. By 2050, AMR is predicted to be responsible for 10 million deaths annually and to cost the world’s economy US$10 trillion [6].

The epidemiology of AMR is complex. Globally, there are spatial differences in AMR bacteria occurrence (or at least detection) [7]. For example, in 2019, the global detected rate for methicillin-resistant Staphylococcus aureus (MRSA) was 12.1%; however, as claimed by the WHO, the rate is not representative as not all member countries provided their
national rate [2]. This lack of reporting of AMR incidence and rates by countries may contribute to global monitoring and detection differences. Reasons for such limitations may include lack of reliable testing, availability of materials, and national AMR surveillance programs, especially in low-income countries [8]. The ability to move people and animals vast distances quickly through air and sea transport and the subsequent intermingling of people from high and low incidence regions is considered a major challenge to global efforts to mitigate the risks posed by AMR [9,10]. Major mass gathering events, such as the Hajj, exacerbate this risk [11].

Mass gatherings are defined by WHO as “the concentration of people at a specific location for a specific purpose over a set period and which has the potential to strain the planning and response resources of the country or community.” [12]. The Hajj pilgrimage is an annual 5–6-day mass gathering that attracts over 2 million people from across the world [13]. The Hajj involves a series of rituals in and around the holy city of Makkah, Saudi Arabia [13].

There have been public health challenges associated with the Hajj in the past. Notably, infectious disease events related to the Hajj have included a cholera epidemic in 1821 that resulted in an estimated 20,000 deaths [14] and meningitis outbreaks in 1987 and 2000, which led to mandating meningococcal vaccination for all pilgrims [15–17]. These events highlight the risk of transmission of infectious diseases at the event [18,19]. The threat of AMR bacteria transmission and global spread associated with the Hajj has been noted as a global health concern [20].

Several researchers have explored AMR-related outbreaks associated with the Hajj [21,22], and, in 2017, a systematic review on AMR events at the Hajj in the preceding 15 years (i.e., 2002–2017) was published [19]. Our research supplements this work and adds to the body of understanding by providing a contemporary (up to December 2021) account of the literature related to AMR and the Hajj. In addition, we offer an account of AMR pathogen-specific incidence and associated antibiotic resistance profiles.

2. Materials and Methods

2.1. Article Identification

A systematic search of the literature using four databases (CINAHL, Embase, PubMed, and Scopus) was conducted between 9 and 20 February 2022. The search was performed by SA. The search strategy involved Medical Subject Headings and keywords related to two domains. These were (i) AMR and (ii) the Hajj. The search strategy is presented in full in Supplementary Material S1.

2.2. Article Screening

The title and abstracts of identified articles were screened independently by two researchers (SA and HB) using established inclusion and exclusion criteria. To be included, an article needed to: be a research paper or lesson from the field-type articles; have been published between 1 January 1990 and 31 December 2021; be available in English; and include content related to AMR bacteria transmission, cases, or outbreaks associated with the Hajj pilgrimage. Articles that were systematic reviews, opinion pieces, or editorials were excluded, as were articles that studied organisms other than bacteria, focused on the biology of AMR, or were not available in English.

2.3. Data Extraction

Articles retained after screening were read in their entirety and data was extracted from them by SA and HB using a pre-developed data collection tool developed in Microsoft Excel (Microsoft Excel 365, Version 16.60, Microsoft Corporation, Redmond, Washington, DC, USA.) (Supplementary Material S2). Data extracted related to (i) the articles’ metadata (authors, title, date of publication, journal); (ii) the pathogen (bacterial species and genus, resistance profile, detection methods, clinical settings, and the number of isolates); and (iii) relationship with the Hajj pilgrimage (Supplementary Material S2).
2.4. Analysis

A mixed method approach to analysis was used. First, we conducted a meta-analysis extracting and tabulating data about AMR cases. Second, we used descriptive statistical method to summarize date. Proportions and confidence (CI) were calculated as per published statistical equations and methods [23–25]. Third, we used deductive and inductive thematic analysis methods to categorize information and distil pertinent themes. The study was undertaken in line with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [26]. Find the PRISMA checklist in Supplementary Material S3.

2.5. Ethics

Ethical approval was not required as this research relied on publicly available data.

3. Results

Of the 2214 studies identified during our systematic search, 51 were retained after screening. Figure 1 summarizes the data collection and screening process. The 51 articles kept were published between 1990 and 2020. The pooled population sample from these studies included in this review was 20,947 participants. The total number of female and male participants were 5566 and 8048, respectively (1:1.4; female to male ratio); sex was not reported by the research papers’ authors for 7333 (35.01%) participants. The average age of cases was 50 years (range from 14 to 101); this did not include one study that focused on children involved in a meningitis outbreak investigation [24]. A summary of these articles is presented in Table 1.

Figure 1. PRISMA flow diagram for the systematic scoping review that includes searches of the databases.
Twenty-six of the 51 papers reported the results of AMR-related research conducted in hospital settings [27–52] while eight were case reports [31,38,40,41,53–56]. One was an outbreak report [21], one hospital-based case-control study [45], and one article was an environmental to detect AMR in Makkah [57].

3.1. What AMR Bacteria Are Reported in the Literature?

Thirty unique AMR bacterial species from 6455 isolates were reported across the 51 articles. These were predominantly enteric or respiratory disease-causing bacteria.

3.1.1. Enteric Disease-Causing AMR Bacteria

Among the enteric disease-causing AMR bacteria, *Escherichia coli* was the most reported in 15 studies [27,32,41–43,46,47,50,58–64]. *Klebsiella* spp. were reported in 13 studies [27,32,40,42,47,49,50,58,59,61,63–65], while *Acinetobacter* spp. [27,32,39,42,45,50,60,63,64] and *Pseudomonas* spp. [27,32,35,42–44,50,51,63] were both each reported in nine studies. Both *Enterobacter* spp. [27,32,42,47,50,64] and *Proteus* spp. [27,32,42,47,50,55] were reported in six studies, *Enterococcus* spp. in four studies [33,34,42,43], *Salmonella* spp. in three studies [27,62,66], and *Citrobacter* spp. in two studies [27,61]. Each of *Bacillus* spp. [57], *Bacteroides* spp. [27], *Brachybacterium* spp. [57], *Burkholderia* spp. [27], *Serratia* spp. [27], *Shigella* spp. [62], *Vibrio cholerae* [53], and *Yersinia enterocolitica* [62] were reported in single studies.

3.1.2. Respiratory Disease-Causing AMR Bacteria

Among the respiratory disease-causing AMR bacteria: *Staphylococcus* spp. in 17 studies [28,30,33,36,37,42,43,48,52,55,57,61,63,64,67–69], *Streptococcus* spp. in seven studies [33,42,65,70–73], *Neisseria meningitidis* in three studies [21,22,54], *Haemophilus influenzae* was reported in two studies [27,32], *Mycobacterium tuberculosis* in two studies [74,75], and *Stenotrophomonas maltophilia* in one study [38].

3.1.3. Other AMR Bacteria

Six non-enteric/non-respiratory disease-causing AMR bacteria were identified. These were *Brucella* spp. [27], *Ewingella Americana* [31], *Helicobacter pylori* [29], *Microbacterium* spp. [57], *Micrococcus* spp. [57], and *Shewanella xiamenensis* [56].

All the organisms reported were found to have resistance to one or more antibiotic class. These results are presented in Table 2. In summary, resistance to beta-lactams class antibiotics was reported for 4856 AMR bacterial isolates in 45 studies [22,27–33,35–53,55–72], to quinolones (including fluoroquinolones) for 1611 AMR bacteria in 24 studies [22,27,29,32,33,35,38,40,42–46,49,50,55,59–61,63,64,67–72], to macrolides for 1161 AMR bacteria in 17 studies [27–29,33,37,43,55,57,61,64,67–70,72,73], to aminoglycosides for 2893 AMR bacteria in 27 studies [27,28,31–33,35,37,38,40,42–45,50,51,57–61,63,64,66–68,74,75], and to sulphonamides for 2504 AMR bacteria in 21 studies [21,27,28,31–33,35,38,40,43,45,53,57,59–61,64,67,70,71,73].
Table 1. Transmission of antimicrobial resistant bacteria in the Hajj.

| Author [Ref.] | Year | AMR Bacteria | Antibiotic Resistance | Study Type | Summary |
|---------------|------|--------------|-----------------------|------------|---------|
| Salih, M. A., et al. [21] | 1990 | Neisseria meningitidis | Sulfadiazine | Outbreak investigation | The outbreak investigation reported 45 AMR-positive Sudanese pilgrims recently returned to Sudan from the Hajj. |
| Ng, P. P. and Taha, M. [53] | 1994 | Vibrio cholerae | Tetracycline, ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole | Case report | The case study reported that tetracycline-resistant *Vibrio cholera* was found in three pilgrims who recently returned to Malaysia from the Hajj. |
| Yousuf, M. and Nadeem, A. [54] | 1995 | Neisseria meningitidis | Cloxacillin | Case report | The case study reported that cloxacillin-resistant *Neisseria meningitidis* was found in two American and Indonesian male pilgrims admitted to a hospital in Madinah, Saudi Arabia. |
| Fatani, M. I., et al. [67] | 2002 | Staphylococcus aureus | Penicillin, erythromycin, cephaplatin, trimethoprim/sulfamethoxazole, clindamycin, tetracycline, gentamicin, and oxacillin | Cross-sectional study (prospective) | The study reported 47 MRSA isolated from pyodermas patients admitted to a hospital in Makkah during the Hajj season. |
| Asghar, A. H. [27] | 2006 | *Escherichia coli*, *Pseudomonas* spp., *Acinetobacter* spp., *Klebsiella* spp., *Serratia* spp., *Enterobacter* spp., *Proteus* spp., *Salmonella* spp., *H. influenzae*, *Citrobacter* spp., *Bacteroides* spp., *Burkholderia* spp., *Brucella* spp. | Ampicillin, cefepime, cephalothin, ceftazidime, amoxicillin/clavulanic acid, cefoxitin, piperacillin/tazobactam, piperacillin, gentamicin, imipenem, aztreonam, amikacin, ciprofloxacin, trimethoprim/sulfamethoxazole, penicillin, oxacillin, erythromycin, and clindamycin | Cross-sectional study (prospective) | The study reported 1530 AMR cases (septicaemic patients) from hospitals in Makkah. |
| Asghar, A. H. and Momenah, A. M. [28] | 2006 | Staphylococcus aureus | Methicillin, penicillin, ampicillin, oxacillin, erythromycin, cephaplatin, gentamicin, Oxycycline, and trimethoprim/sulfamethoxazole | Cross-sectional study (prospective) | The study reported 199 MRSA cases from hospitals in Makkah, of which 157 were found to have MDR. |
| Karima, T. M., et al. [29] | 2006 | Helicobacter pylori | Metronidazole, erythromycin, amoxicillin, tetracycline, and ciprofloxacin | Cross-sectional study (prospective) | The study reported that *H. pylori* was found in 18 patients (from a general hospital in Makkah) with resistance to at least one antibiotic. |
### Table 1. Cont.

| Author [Ref.] | Year | AMR Bacteria | Antibiotic Resistance | Study Type | Summary |
|---------------|------|--------------|-----------------------|------------|---------|
| Memish, Z. A., et al. [30] | 2006 | *Staphylococcus aureus* | Methicillin | Cross-sectional study (prospective) | The study reported six MRSA isolates from pilgrims during the Hajj of 2004. |
| Bukhari, S. Z., et al. [31] | 2008 | *Ewingella americana* | | Case report | The case report of an AMR *E. americana* strain, isolated from an Indonesian pilgrim admitted to a hospital in Makkah during the Hajj. |
| Asghar, A. H. and Faidah, H. S. [32] | 2009 | *Escherichia coli, Klebsiella pneumoniae, Klebsiella spp., P. aeruginosa, A. baumannii, Proteus spp., H. influenzae, Enterobacter spp.* | Cephalothin, cefoxitin, cefuroxime, ceftazidime, cefotaxime, ceftiraxone, ampicillin, aztreonam, piperacillin, piperacillin/tazobactam, amoxicillin/clavulanic acid, imipenem, meropenem, imipenem/cilastatin, amikacin, gentamycin, tobramycin, ciprofloxacin, levofloxacin, norfloxacin, nalidixic acid, norfloxacin/ciprofloxacin, tetracycline, trimethoprim/sulfamethoxazole, and nitrofurantoin | Cross-sectional study (prospective) | The study found 1046 g-negative bacteria isolated from patients in Makkah hospitals were resistant to at least one antibiotic. |
| Abulreesh, H. H. and Organji, S. R. [69] | 2011 | *Staphylococci* | Erythromycin, colistin, penicillin, oxacillin, vancomycin | Cross-sectional study (prospective) | The study reported 19 vancomycin-resistance *Staphylococci*, isolated from food and food handlers in Makkah. |
| Author [Ref.] | Year | AMR Bacteria | Antibiotic Resistance | Study Type | Summary |
|---------------|------|--------------|----------------------|------------|---------|
| Asghar, A. H. [33] | 2011 | *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*, *Streptococcus viridans*, *Enterococcus Fecalis*, and *Enterococcus spp.* | Cephalexin, cefazolin, cefoxitin, cefotaxime, ceftriaxone, ceftazidime, cefuroxime, ceftizoxime, penicillin, ampicillin, ampicillin/sulbactam, oxacillin, aztreonam, amoxicillin/clavulanic acid, imipenem/cilastatin sodium, gentamicin, neomycin, amikacin, ciprofloxacin, ciprofloxacin/norfloxacin, nalidixic acid, gemifloxacin, levofloxacin, vancomycin, erythromycin, clindamycin, quinupristin/dalfopristin, linezolid, tetracycline, chloramphenicol, trimethoprim/sulfamethoxazole, rifampicin, nitrofurantoin, and polymyxin B | Cross-sectional study (prospective) | The study of patients admitted to hospitals in Makkah found that the most common resistance reported was against beta-lactams. |
| El-Amin, N. M. and Faidah, H. S. [34] | 2011 | *Enterococci* | Vancomycin | Cross-sectional study (retrospective) | The retrospective study reported vancomycin-resistant Enterococci infections in seven patients from hospitals in Makkah. |
| Asghar, A. H. [35] | 2012 | *Pseudomonas aeruginosa* | Amikacin, amoxicillin/clavulanic acid, ampicillin, aztreonam, cefepime, cefotaxime, gentamicin, ceftriaxone, cefoxitin, ceftazidime, cefuroxime, cephalothin, ciprofloxacin, imipenem, meropenem, piperacillin, piperacillin/tazobactam, tetracycline, and trimethoprim/sulfamethoxazole | Cross-sectional study (prospective) | The study reported that metallo-beta-lactamase (MBL) -producing *P. aeruginosa* were identified in 76 patients (from 30 nationalities) admitted to hospitals in Makkah. |
| Author                  | Year | AMR Bacteria                                                                 | Antibiotic Resistance                                                                 | Study Type                      | Summary                                                                                                                                 |
|------------------------|------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Asghar, A. H. [36]     | 2014 | *Staphylococcus aureus*                                                      | Methicillin                                                                            | Cross-sectional study (prospective) | The study reported that MRSA was identified in 114 patients admitted to hospitals in Makkah, of which 100 carried the mecA gene.    |
| Khan, M. M., et al. [37]| 2014 | *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Staphylococcus hominis-hominis*, *Staphylococcus hominis-novo*, *Staphylococcus warneri*, *Staphylococcus hominis*, *Staphylococcus capitis*, *Staphylococcus lugdunensis*, and *Staphylococcus auricularis* | Ampicillin, amoxicillin/clavulanic acid, azithromycin, clindamycin, daptomycin, erythromycin, gentamicin, oxacillin, penicillin, and quinupristin/dalfopristin | Cross-sectional study (prospective) | The study reported that 189 coagulase negative staphylococci (CoNS) isolates (from neonates admitted to a hospital in Makkah) were resistant to at least one of the tested antibiotics. |
| Abdel-Haleem, A. M., et al. [38] | 2015 | *Stenotrophomonas maltophilia*                                                | Beta-lactams, cephalosporins, carbapenems, aminoglycosides, fluoroquinolones, tetracyclines, polymyxin, trimethoprim, gentamicin, and tigecycline | Case report                     | The case study reported MDR *S. maltophilia* strain was isolated from a patient with reoccurring urinary tract infection admitted to a tertiary hospital in Makkah. |
| Alyamani, E. J., et al. [39] | 2015 | *Acinetobacter baumannii*                                                     | Cefepime, ceftazidime, and multidrug resistance                                         | Cross-sectional study (prospective) | The study reported 100 MDR *A. baumannii* isolates collected from patients admitted to hospitals in Makkah.                              |
| Memish, Z. A., et al. [70] | 2015 | *Streptococcus pneumoniae*                                                   | Penicillin, amoxicillin, cefotaxime, chloramphenicol, clindamycin, erythromycin, levofloxacin, moxifloxacin, tetracycline, or sulfamethoxazole/trimethoprim | Cross-sectional study (prospective) | The study reported 137 AMR positive pilgrims returning from the Hajj to their home countries (Algeria, Chad, Comoros, Egypt, Ethiopia, Guinea, India, Indonesia, Libya, Mauritania, Nigeria, and Sudan). |
| Olaitan, A. O., et al. [66] | 2015 | *Salmonella enterica*                                                        | Colistin, amoxicillin, amoxicillin/clavulanic acid, ceftriaxone, aztreonam, ceftazidime, imipenem, and gentamicin | Cross-sectional study (prospective) | The study reported MDR *Salmonella* in five French pilgrims who recently returned to Marseille, France after the Hajj.              |
| Author [Ref.] | Year | AMR Bacteria | Antibiotic Resistance | Study Type | Summary |
|---------------|------|--------------|-----------------------|------------|---------|
| Algowaihi, R., et al. [40] | 2016 | *Klebsiella pneumoniae* | Amikacin, amoxicillin/clavulanic acid, ampicillin, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, cefturoxime, ciprofloxacin, ertapenem, fosfomycin, gentamicin, imipenem, levofloxacin, meropenem, mezlocillin, moxifloxacin, nitrofurantoin, norfloxacin, piperacillin/tazobactam, tetracycline, tigecycline, tobramycin, trimethoprim, and sulfamethoxazole | Case report | The study reported MDR *K. pneumoniae* strain isolated from a female patient with a urinary tract infection, admitted to a tertiary hospital in Makkah. |
| Alyamani, E. J., et al. [41] | 2016 | *Escherichia coli* | Penicillin, carbapenems, cephamycin, tetracycline, chloramphenicol, acriflavine, and polymyxin | Case report | The case study reported MDR uropathogenic *Escherichia coli* O25b:H4 strain isolated from a male patient admitted to a hospital in Makkah. |
| Haseeb, A., et al. [42] | 2016 | *Acinetobacter baumannii, Escherichia coli, Enterobacter cloacae, Enterococcus spp., Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Salmonella, Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus spp.* | Amoxicillin/clavulanic acid, ampicillin, aztreonam, cefazolin, cefepime, cefoxitin, ceftazidime, cefotaxime, ceftriaxone, cephalothin, ertapenem, imipenem, meropenem, oxacillin, penicillin, piperacillin/tazobactam, ticarcillin, mezlocillin, amikacin, gentamicin, tobramycin, ciprofloxacin, levofloxacin, moxifloxacin, nalidixic acid, and norfloxacin | Cross-sectional study (retrospective) | The retrospective study reported 214 AMR bacterial isolates collected from pilgrims who visited emergency care departments of Makkah hospitals. |
| Author [Ref.] | Year | AMR Bacteria | Antibiotic Resistance | Study Type | Summary |
|---------------|------|---------------|-----------------------|------------|---------|
| Johargy, A. K. [43] | 2016 | *Enterococcus faecium, Escherichia coli, Staphylococcus aureus* and *P. aeruginosa* | Amoxicillin/clavulanic acid, amikacin, ceftazidime, cefalothin, erythromycin, gentamicin, chloramphenicol, oxacillin, clindamycin, ciprofloxacin, penicillin, vancomycin, piperacillin, cefotaxime, nalidixic acid, nitrofurantoin, oxacillin, and sulfamethoxazole | Cross-sectional study (prospective) | The study reported 129 AMR bacterial isolates collected from diabetic patients from hospitals in Makkah. |
| Khan, M. A. and Faiz, A. [44] | 2016 | *Pseudomonas aeruginosa* | Amikacin, aztreonam, cefepime, ceftazidime, ciprofloxacin, gentamicin, imipenem, levofloxacin, meropenem, piperacillin, piperacillin/tazobactam, and ticarcillin | Cross-sectional study (prospective) | The study reported 27 AMR and 8 MDR *P. aeruginosa* isolates collected from patients admitted to hospitals in Makkah. |
| Leangapichart, T., et al. [58] | 2016 | *Escherichia coli* and *Klebsiella pneumoniae* | Ticarcillin/clavulanic acid, ceftriaxone, and gentamicin | Cross-sectional study (prospective) | The study reported 28 AMR *Escherichia coli* or *K. pneumoniae* isolates collected from French pilgrims before and after the Hajj. |
| Leangapichart, T., et al. [59] | 2016 | *Escherichia coli* and *Klebsiella pneumoniae* | Amoxicillin, amoxicillin/clavulanic acid, ceftriaxone, ciprofloxacin, fosfomycin, gentamicin, nalidixic acid, and sulfamethoxazole/trimethoprim | Cross-sectional study (prospective) | A letter to editor reporting the presence of colistin-resistance gene, mcr-1 among 23 French pilgrims (before and after the Hajj of 2013 and 2014), ten of which were *Escherichia. coli*, and one was *K. pneumoniae*. |
| Leangapichart, T., et al. [60] | 2016 | *Acinetobacter baumannii* and *Escherichia coli* | Aztreonam, cefotixin, ceftriaxone, cefotaxime, amoxicillin/clavulanic acid, ticarcillin/clavulanic acid, amoxicillin, tobramycin, gentamicin, ciprofloxacin, ofloxacin, imipenem, and sulfamethoxazole/trimethoprim | Cross-sectional study (prospective) | A study reporting MDR *A. baumannii* and *Escherichia coli* among 43 French pilgrims (before and after returning from the Hajj of 2014) |
Table 1. Cont.

| Author [Ref.]                  | Year | AMR Bacteria                                                                 | Antibiotic Resistance                                                                 | Study Type                              | Summary                                                                                     |
|--------------------------------|------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------|---------------------------------------------------------------------------------------------|
| Marglani, O. A., et al. [61]   | 2016 | Staphylococcus aureus, Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Enterobacter spp., and Citrobacter spp. | Amoxicillin/clavulanic acid, ampicillin, cefoxitin, cefepime, cefazidime, ceftriaxone, ciprofloxacin, levofloxacin, gentamicin, imipenem, piperacillin/tazobactam, sulfamethoxazole/trimethoprim, clindamycin, azithromycin, erythromycin, tetracycline, and vancomycin | Cross-sectional study (prospective)       | A study reporting 57 AMR isolates collected from pilgrims with acute rhinosinusitis) during the Hajj of 2014. |
| Memish, Z. A., et al. [71]     | 2016 | Streptococcus pneumoniae                                                     | Erythromycin, clindamycin, tetracycline, penicillin, amoxicillin, cefotaxime, levofloxacin, moxifloxacin, chloramphenicol, and sulfamethoxazole/trimethoprim | Cross-sectional study (prospective)       | The study reported 94 AMR S. pneumoniae isolates collected from pilgrims (before and during the Hajj of 2013) from 12 countries in Africa, Asia, USA, and Europe. |
| Abd El Ghany, M., et al. [62]  | 2017 | Salmonella spp., Shigella spp., and Escherichia coli, Yersinia enterocolitica | Beta-lactams                                                                          | Cross-sectional study (prospective)       | The study reported 70 AMR bacterial isolates collected from pilgrims (from 40 different countries) who acquired enteric infections during the Hajj of 2011 to 2013. |
| Abulreesh, Hussein H., et al. [68] | 2017 | Staphylococcus aureus                                                        | Amoxicillin/clavulanic acid, ampicillin, azithromycin, cefoxitin, clindamycin, erythromycin, fusidic acid, gentamicin, imipenem, oxacillin, penicillin, and tetracycline | Cross-sectional study (prospective)       | The study reported 50 AMR S. aureus isolates collected from clinical laboratories in Makkah. |
| Al-Gethamy, M. M., et al. [45] | 2017 | Acinetobacter baumannii                                                     | Cefazidime, ciprofloxacin, imipenem, trimethoprim, amikacin, gentamicin.             | Case-control study                       | The case–control study reported MDR A. baumannii isolates (collected from patients admitted to a hospital in Makkah), that mainly resistance to imipenem and gentamycin with 83% and 73%, respectively. |
| Alyamani, E. J., et al. [46]   | 2017 | Escherichia coli                                                             | Ampicillin, cefoxitin, ciprofloxacin, cefepime, aztreonam, cefotaxime, and ceftazidime | Cross-sectional study (prospective)       | The study reported 58 AMR Escherichia coli isolates, collected from pilgrims admitted hospitals in Makkah, during the Hajj of 2014 and 2015. |
| Author [Ref.] | Year | AMR Bacteria | Antibiotic Resistance | Study Type | Summary |
|--------------|------|--------------|-----------------------|------------|---------|
| Ahmed Khan, T., et al. [55] | 2018 | *Staphylococcus aureus* and *Proteus* spp. | Ampicillin, ciprofloxacin, fusidic acid, penicillin, cefuroxime, ceftriaxone, cefixime, erythromycin, cefoxitin, and tetracycline | Case report | The case study reported MDR *S. aureus* and *proteus* spp. isolates, collected from a burn aggravated infected foot wart in a pilgrim who came from Pakistan to perform the Hajj of 2017. |
| Ganaie, F, et al. [72] | 2018 | *Streptococcus pneumoniae* | Penicillin, cefotaxime, levofloxacin, erythromycin, tetracycline, and sulfamethoxazole/trimethoprim | Cross-sectional study (prospective) | The study reported 145 AMR *S. pneumoniae* isolates, collected from Indian pilgrims before and after returning from the Hajj of 2016, with higher AMR rates within the post-Hajj samples. |
| Khan, M. A., et al. [47] | 2019 | *Klebsiella pneumoniae*, *Escherichia coli*, *E. cloacae* and *Proteus mirabilis* | Cephalosporins (ceftazidime, cefotaxime, ceftriaxone, cefepime) and carbapenems | Cross-sectional study (prospective) | The study reported 27 carbapenemase Enterobacteriaceae isolates (collected from patients admitted to hospitals in Makkah), of which 21 were carbapenemase producing *K. pneumoniae*. |
| Mater, M. E., et al. [48] | 2020 | *Staphylococcus aureus* | methicillin | Cross-sectional study (retrospective) | The retrospective study reported 92 MRSA isolates, collected from burn and paediatric patients admitted to a hospital in Makkah, from January 2016 to January 2017. |
| Sambas, MFMK, et al. [74] | 2020 | *Mycobacterium tuberculosis* | Streptomycin, isoniazid, ethambutol, and rifampicin, | Cross-sectional study (prospective) | The study reported 27 AMR Tuberculosis (TB) isolates and 8 MDR-TB isolates, collected from TB patients admitted to a hospital in Makkah. |
| Willerton, L., et al. [22] | 2020 | *Neisseria meningitidis* | Penicillin and ciprofloxacin | Cross-sectional study (retrospective) | The retrospective study reported penicillin and ciprofloxacin *N. meningitidis* isolates, from *N. meningitidis* patients returning from Makkah, after preforming umrah pilgrimage to England. |
| Ahmed, O. B., et al. [49] | 2021 | *Klebsiella pneumoniae* | Amoxicillin/clavulanic acid, ciprofloxacin, ceftaxime, ampicillin, aztreonam, cefuroxime, cefepime, and imipenem | Cross-sectional study (retrospective) | The retrospective study reported 51 aminoglycoside-resistant *K. pneumonia* isolates, collected from hospital admitted patients in Makkah. |
| Ahmed, Omar B., et al. [50] | 2021 | *Klebsiella pneumoniae*, *Escherichia coli*, *P. aeruginosa*, *A. baumannii*, *K. oxytoca*, *P. mirabilis*, and Enterobacter spp. | Tobramycin, kanamycin, gentamicin, neomycin, amikacin, streptomycin, cefotaxime, amoxicillin/clavulanic acid, and ciprofloxacin | Cross-sectional study (retrospective) | The retrospective study reported 69 g-negative bacterial isolates with aminoglycoside-resistant gene(s), collected from hospital admitted patients in Makkah. |
| Author [Ref.] | Year | AMR Bacteria | Antibiotic Resistance | Study Type | Summary |
|---------------|------|--------------|-----------------------|------------|---------|
| Al-Hayani, A. M, et al. [75] | 2021 | *Mycobacterium tuberculosis* | isoniazid, streptomycin, ethambutol, rifampicin, and pyrazinamide | Cross-sectional study (retrospective) | The retrospective study reported 93 TB patients with AMR, where data collected from the registry of the Central TB Laboratory in Makkah. |
| Al-Zahrani, I. A. and Al-Ahmadi, B. M. [51] | 2021 | *Pseudomonas aeruginosa* | Beta-lactams, amikacin, and colistin | Cross-sectional study (prospective) | The study reported 35 carbapenem-resistant *P. aeruginosa* isolates, collected from 26 hospital admitted patients in Makkah. |
| Alghamdi, S. [63] | 2021 | *Acinetobacter* species, *Klebsiella pneumoniae*, *Escherichia coli*, *Staph. aureus* species and *Pseudomonas aeruginosa*. | Cefoxitin, penicillin, gentamicin, ampicillin, methicillin, clindamycin, sulfamethoxazole/trimethoprim, vancomycin, Trimoxazole, linezolid, ciprofloxacin, levofloxacin, cefuroxime, amikacin, ceftazidime, cefepime, and ceferazone/sulbactam | Cross-sectional study (retrospective) | The retrospective study reported 123 AMR bacterial isolates, 15 were MRSA, and 6 MDR *Acinetobacter* spp. isolates, collected from cancer patients who were admitted to Makkah hospitals. |
| Harimurti, K., et al. [73] | 2021 | *Streptococcus pneumoniae* | Erythromycin, clindamycin, chloramphenicol, penicillin, sulfamethoxazole/trimethoprim, and tetracycline | Cross-sectional study (prospective) | The study reported 85 AMR *S. pneumoniae* isolates, collected from Indonesian pilgrims before and after the Hajj of 2015. |
| Hoang, V. T., et al. [64] | 2021 | *Enterobacter aerogenes*, *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, *Staphylococcus aureus*, *Acinetobacter baumannii* | Imipenem, doripenem, piperacillin/tazobactam, fosfomycin, sulfamethoxazole/trimethoprim, ciprofloxacin, ticarcillin, ticarcillin/clavulanic acid, tobramycin, fusidic acid, erythromycin, methicillin, amoxicillin/clavulanic acid, cefepime, ceftiraxone, and colistin | Cross-sectional study (prospective) | The study reported 81 MDR isolates, collected from pilgrims from Marseille, France, during the Hajj of 2017 and 2018, of which 23 were isolated from pre-Hajj, and 52 from post-Hajj. |
| Leangapichart, T., et al. [56] | 2021 | *Shewanella xiamensis* | Amoxicillin, amoxicillin/clavulanic acid, and ticarcillin/clavulanic acid | Case report | The case study reported two beta-lactam resistant *S. xiamensis* strains, isolated from a Moroccan pilgrim from France, one before and one during travels to the Hajj of 2013. |
Table 1. Cont.

| Author [Ref.]          | Year | AMR Bacteria                                      | Antibiotic Resistance                               | Study Type                          | Summary                                                                                                                                                                                                 |
|------------------------|------|---------------------------------------------------|-----------------------------------------------------|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mohd Baharin, I. E., et al. [65] | 2021 | *Streptococcus pneumoniae* and *Klebsiella pneumoniae* | Beta-lactams and macrolide                          | Cross-sectional study (prospective) | The study reported 14 AMR *K. pneumoniae* and *S. pneumoniae* isolates, collected from Malaysian pilgrims returning to Kelantan, Malaysia from the Hajj.                                                                                       |
| Turkistani, M. A., et al. [57] | 2021 | *Staphylococcus spp.*, *Micrococcus spp.*, *Bacillus spp.*, *Geobacillus spp.*, *Brachybacterium spp.* | Penicillin, erythromycin, ampicillin, chloramphenicol, clindamycin, gentamicin, sulfamethoxazole/trimethoprim, fusidic acid, oxacillin, and ceftazidime | Environmental study                  | The environmental research study reported 40 AMR bacterial isolates, collected from surface swab samples from two membership-based gyms in Makkah.                                                                                     |
| Haseeb, A., et al. [52] | 2022 | *Staphylococcus aureus*, non-fermenter Gram-negative bacilli, *Enterobacteriaceae*, *Enterococci.* | Methicillin, beta-lactams, carbapenems, third generation cephalosporins, and vancomycin. | Cross-sectional study (prospective) | The study reported 106 AMR isolates and 46 MRSA isolates, collected from patients admitted to Makkah hospitals.                                                                                       |

ESBL = extended spectrum beta-lactamase; MDR = multidrug resistant; NA = not available.

Table 2. The number of antimicrobial resistant (AMR) isolates that were reported in literature, published from 1990 to 2021, related to AMR bacteria within the Hajj. Each bacterial species isolates are categorized by their resistance to the five main antibiotic classes.

| Organism(s) Name | Aminoglycoside | Beta-Lactams | Macrolides | Quinolones | Sulphonamides |
|------------------|----------------|--------------|------------|------------|--------------|
|                  | Number of AMR Isolates | Reported in (n) Studies | Number of AMR Isolates | Reported in (n) Studies | Number of AMR Isolates | Reported in (n) Studies | Number of AMR Isolates | Reported in (n) Studies | Number of AMR Isolates | Reported in (n) Studies |
| Enteric bacteria | 393            | 8            | 491        | 9          | 0            | 0            | 316            | 7            | 323            | 5            |
| Acinetobacter spp. | 0              | 0            | 3          | 0          | 0            | 0            | 316            | 7            | 1              | 1            |
| Bacillus spp. | 3              | 1            | 2          | 1          | 0            | 0            | 1              | 1            | 1              | 1            |
| Bacteroides spp. | 0              | 0            | 1          | 1          | 0            | 0            | 0              | 0            | 1              | 1            |
| Brachybacterium spp. | 2              | 1            | 2          | 1          | 0            | 0            | 1              | 1            | 1              | 1            |
| Burkholderia spp. | 4              | 2            | 8          | 2          | 0            | 0            | 3              | 1            | 2              | 1            |
| Citrobacter spp. | 25             | 4            | 69         | 6          | 0            | 0            | 18             | 3            | 32             | 3            |
| Enterobacter spp. | 68             | 2            | 176        | 2          | 56           | 2            | 39             | 1            | 21             | 1            |
| Enterococcus spp. | 489            | 9            | 726        | 13         | 18           | 1            | 407            | 9            | 426            | 5            |
| Escherichia coli |                 |              |            |            |              |              |                 |              |                 |              |
| Organism(s) Name          | Aminoglycoside | Beta-Lactams | Macrolides | Quinolones | Sulphonamides |
|---------------------------|----------------|--------------|------------|------------|--------------|
|                           | Number of      | Number of    | Number of  | Number of  | Number of    |
|                           | Reported AMR   | Reported AMR | Reported   | Reported   | Reported     |
|                           | Isolates      | Isolates     | in (n)     | in (n)     | in (n)       |
|                           | Reported in    | Reported in  | Studies    | Studies    | Studies      |
|                           | (n) Studies    | (n) Studies  |            |            |              |
| Klebsiella spp.           | 339            | 475          | 8          | 0          | 264          |
|                           | 5              | 8            | 0          | 0          | 6            |
|                           | 475            | 8            | 0          | 0          | 264          |
|                           | 8             | 0            | 0          | 0          | 6            |
|                           | 242            | 4            |            |            |              |
| Proteus spp.              | 51             | 74           | 4          | 0          | 45           |
|                           | 2              | 4            | 0          | 0          | 2            |
|                           | 74            | 4            | 0          | 0          | 45           |
|                           | 4             | 0            | 0          | 0          | 2            |
|                           | 29            | 2            |            |            |              |
| Pseudomonas spp.          | 736            | 800          | 5          | 0          | 397          |
|                           | 5              | 5            | 0          | 0          | 397          |
|                           | 800           | 5            | 0          | 0          | 397          |
|                           | 5             | 0            | 0          | 0          | 397          |
|                           | 240           | 2            |            |            |              |
| Salmonella spp.           | 3              | 34           | 3          | 0          | 0            |
|                           | 2              | 3            | 0          | 0          | 0            |
|                           | 34            | 3            | 0          | 0          | 0            |
|                           | 0             | 0            | 0          | 0          | 0            |
|                           | 7             | 1            |            |            |              |
| Serratia spp.             | 4              | 21           | 1          | 0          | 1            |
|                           | 1              | 1            | 0          | 0          | 1            |
|                           | 21            | 1            | 0          | 0          | 1            |
|                           | 0             | 0            | 0          | 0          | 0            |
|                           | 7             | 1            |            |            |              |
| Shigella spp.             | 0              | 9            | 1          | 0          | 0            |
|                           | 0              | 1            | 0          | 0          | 0            |
|                           | 9             | 1            | 0          | 0          | 0            |
|                           | 0             | 0            | 0          | 0          | 0            |
|                           | 0             | 0            |            |            |              |
| Vibrio cholerae           | 0              | 3            | 1          | 0          | 0            |
|                           | 0              | 1            | 0          | 0          | 0            |
|                           | 3             | 1            | 0          | 0          | 0            |
|                           | 0             | 0            | 0          | 0          | 0            |
|                           | 3             | 1            |            |            |              |
| Yersinia enterocolitica   | 0              | 3            | 1          | 0          | 0            |
|                           | 0              | 1            | 0          | 0          | 0            |
|                           | 3             | 1            | 0          | 0          | 0            |
|                           | 0             | 0            | 0          | 0          | 0            |
|                           | 0             | 0            |            |            |              |
| Respiratory bacteria      | 38             | 47           | 2          | 0          | 15           |
| Haemophilus influenzae    | 2              | 2            | 0          | 0          | 1            |
|                           | 47            | 2            | 0          | 0          | 1            |
|                           | 2             | 0            | 0          | 0          | 1            |
|                           | 38            | 2            |            |            |              |
| Neisseria meningitidis    | 0              | 5            | 2          | 0          | 3            |
|                           | 0              | 2            | 0          | 0          | 3            |
|                           | 5             | 2            | 0          | 0          | 3            |
|                           | 45            | 1            |            |            |              |
| Staphylococcus spp.       | 621            | 1748         | 16         | 818        | 57           |
|                           | 9              | 16           | 818        | 57         | 4            |
|                           | 1748          | 16           | 818        | 57         | 4            |
|                           | 696           | 6            |            |            |              |
| Stenotrophomonas maltophilia | 1          | 100          | 1          | 100        | 1            |
|                           | 100           | 1           | 100        | 1          | 100          |
|                           | 100           | 1           |            | 1          |              |
|                           | 100           | 1           |            | 1          |              |
| Streplococcus spp.        | 113            | 146          | 1          | 266        | 43           |
|                           | 1              | 1           | 266        | 43         | 1            |
|                           | 146           | 1           | 266        | 43         | 1            |
|                           | 380           | 1            |            | 1          |              |
| Other bacteria            | 1              | 1            | 1          | 0          | 0            |
| Brucella spp.             | 1              | 1            | 1          | 0          | 0            |
|                           | 1              | 1            | 1          | 0          | 0            |
|                           | 1             | 1            | 1          | 0          | 0            |
|                           | 1             | 1            | 1          | 0          | 0            |
| Ewingella americana       | 1              | 1            | 1          | 0          | 0            |
|                           | 1              | 1            | 1          | 0          | 0            |
|                           | 1             | 1            | 1          | 0          | 0            |
|                           | 1             | 1            | 1          | 0          | 0            |
| Helicobacter pylori       | 0              | 0            | 2          | 1          | 0            |
|                           | 0              | 0            | 2          | 1          | 0            |
|                           | 2             | 1            | 0          | 0          | 0            |
|                           | 2             | 1            |            |            |              |
| Microbacterium spp.       | 0              | 0            | 6          | 1          | 1            |
|                           | 0              | 0            | 6          | 1          | 1            |
|                           | 0             | 0            | 0          | 0          | 0            |
|                           | 0             | 0            |            |            |              |
| Micrococcus spp.          | 0              | 0            | 1          | 1          | 0            |
|                           | 0              | 0            | 1          | 1          | 0            |
|                           | 0             | 0            | 0          | 0          | 0            |
|                           | 0             | 0            |            |            |              |
| Stenovella xiamenensis    | 1              | 1            | 1          | 0          | 0            |
|                           | 1              | 1            | 1          | 0          | 0            |
|                           | 1             | 1            | 1          | 0          | 0            |
|                           | 1             | 1            |            |            |              |

NA = not applicable; spp. = species; n = number of studies.
The next part of the manuscript discusses key data by key theme. The themes are (i) how AMR was detected; (ii) the geospatial distribution of AMR cases reported in the literature; and (iii) the resistance profile. For consistency with the previous section and where relevant, results are presented as those related to enteric disease-causing and respiratory-illness-causing AMR.

3.2. The Methods of Detecting AMR Bacteria

The method by which AMR was detected was reported in 46 of the 51 papers. The most common method used was disc diffusion (\(n = 26\) studies) [21,27–30,34,36,43,47,49, 50,54–58,60,61,64,66–71,73], followed by polymerized chain reaction (PRC) (\(n = 21\) studies) [35,36,38–41,46,47,50,51,56,58–60,62,64–66,68,70,71]. Automated identification systems were used (\(n = 14\) studies) [30,31,33,35,37,39,43,44,46,51,61,63,72,75], two of which used molecular assay kits also [30,46]. Gradient strip diffusion was used in two studies [22,68]. Data from patients’ medical records were extracted in five studies to determine AMR status [32,42,45,48,74]; the specific diagnostic methods used were not reported.

3.3. The Geospatial Distribution of AMR Cases Reported

Our review found evidence for AMR bacteria among pilgrims travelling to the Hajj or returning from it from five continents. Nine studies reported 1422 Hajj-associated AMR cases from 20 Asian countries [53–55,62,65,70–73]; four studies reported 286 cases from 16 African countries [21,62,70,71]; two studies reported six cases from two North American countries [62,71]; nine studies reported 2069 cases from two European countries [22,56,58–60,62,64,66,71]. One study reported one case from Australia [62]. Most research articles (\(n = 34\)) and AMR resistant isolates (5686 resistant isolates of 8035 tested samples (70.77% [95% CI: 69.77%–71.76%]) were identified in Makkah, the city in which the Hajj takes place and from where most pilgrims come [27–52,57,61,63,67–69,74,75].

3.3.1. Geospatial Distribution of Enteric Disease-Causing AMR Bacteria

Eight articles discussed 2802 enteric disease-causing AMR bacteria isolates (out of 3315 tested) among travelling Hajj pilgrims, two studies for pilgrims returning to Asia (Malaysia) [53,65], five of pilgrims returning to Europe (France) [58–60,64,66]. One had a mixed cohort of pilgrims from 40 countries (Afghanistan, Algeria, Australia, Azerbaijan, Bangladesh, Benin, Burma, Canada, Chad, China, Egypt, Ethiopia, Ghana, Guinea, India, Indonesia, Iraq, Jordan, Kazakhstan, Mali, Malaysia, Morocco, Mauritania, Nepal, Niger, Nigeria, Oman, Pakistan, Palestine, Philippines, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, Turkey, UK, Union des Comoros, USA, and Yemen) [62].

3.3.2. Geospatial Distribution of Respiratory Illness-Causing AMR Bacteria

Eleven articles studied 1330 respiratory illness-causing AMR bacteria (out of 2145 tested) isolated from travelling pilgrims, and five studies for pilgrims who had travelled from Asia (India and Pakistan) to the Hajj [55,72], or vice versa (India, Indonesia, Saudi Arabia, and Malaysia) [54,65,72,73]. Moreover, one study looked at an outbreak caused by returning pilgrims to Africa (Sudan) [21]. Three studies reported AMR among pilgrims returning to Europe (the UK and France) [22,56,64], or vice versa (France) [56,64]. Two studies looked at respiratory illness-causing AMR bacteria among pilgrims traveling from different countries (12 countries in Africa, Asia, USA, and Europe) to the Hajj [71] or returning from Hajj (Algeria, Chad, Comoros, Egypt, Ethiopia, Guinea, India, Indonesia, Libya, Mauritania, Nigeria, and Sudan) [70].

3.4. The Resistance Profile for AMR Bacteria

3.4.1. Resistance Profile of Enteric Disease-Causing AMR Bacteria

Enteric bacteria have expressed beta-lactam resistance (including cephalosporin resistance) in 3050 out of 4220 isolates documented in 28 related studies reviewed [27,32,33,35,40–
In this review, most enteric bacteria were found in hospital settings, with a total of 3632 isolates within 18 studies [27,32–35,39–47,49–52]. Except for fosfomycin, resistance to antibiotics such as macrolides, lincosamides, and glycopeptides was reported only in hospital settings related to the Hajj, with 89, 67, and 158 isolates, respectively. 

Acinetobacter spp. and Pseudomonas aeruginosa are examples of enteric organisms reported in the included studies. All AMR Acinetobacter spp. that are found related to the Hajj were 361 out of 526 Acinetobacter spp. isolates (68.63% [95% CI: 64.67%–72.60%]) reported in nine studies [27,32,42,45,50,59,63,64]. Most of the studies (five) were exploratory, as they tested for multiple possible organisms for isolates from multiple diseases and conditions [32,42,50,59,64]. Six studies found 348 out of 471 AMR Acinetobacter spp. (73.89% [95% CI: 69.92%–77.85%]) were isolated within hospital settings [27,32,39,45,50,63]. On the other hand, AMR Pseudomonas aeruginosa were a total of 466 out of 984 (47.36% [95% CI: 44.24%–50.48%]) Pseudomonas aeruginosa isolates. All were reported within six studies, and all were within hospital settings [32,35,42–44,51]. Most of the studies (13 out of 15 studies) that tested for AMR Acinetobacter spp. and Pseudomonas aeruginosa discussed the possible effect of overuse and misuse of antibiotics on the development of AMR enteric bacteria, and most emphasize the importance of surveillance and monitoring programs to reduce the burden of such resistance profiles.

### 3.4.2. Resistance Profile of Respiratory Illness-Causing AMR Bacteria

There were 29 studies reporting AMR respiratory colonizing or infecting bacteria [21,22,27,28,30,32,36–38,42,43,48,52,54,55,57,61,63–65,67–75]. Methicillin-resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis (TB) are two important respiratory-related infections that merit further investigation.

Regarding MRSA, 14 out of 16 studies that tested for resistant Staphylococcus aureus found 933 out of 2164 MRSA isolates (43.11% [95% CI: 41.03%–45.20%]) within their studies [27,28,30,33,36,42,43,48,52,61,63,64,67,68]. Furthermore, nine studies reported 881 out of 1983 MRSA (44.43% [95% CI: 42.24%–46.61%]) isolated within hospital settings [27,28,30,33,36,42,43,48,52]. Table 3 compares the rate of selected AMR reported within the studies found in enteric and respiratory disease-causing bacteria isolated within hospital settings.

#### Table 3. Rates of selected antibiotic resistances for enteric and respiratory disease-causing bacteria isolated in hospital settings.

| Antibiotic Class | AMR Rate among Respiratory Disease–Causing Bacteria Isolated in Hospital Settings (n = 1824) | AMR Rate among Enteric Disease–Causing Bacteria Isolated in Hospital Settings (n = 3632) |
|------------------|-------------------------------------------------|---------------------------------|
|                  | u (%)                                           | 95% CI (%)                      | u (%) | 95% CI (%) |
| Aminoglycoside   | 561                                             | 30.76 [28.64–32.87]             | 1996  | 54.96 [53.34–56.57] |
| Beta–lactams     | 1424                                            | 78.07 [76.17–79.97]             | 2730  | 75.17 [73.76–76.57] |
| Lincosamides     | 359                                             | 19.68 [17.86–21.51]             | 67    | 1.84 [1.41–2.28] |
| Macrolides       | 693                                             | 37.99 [35.77–40.22]             | 89    | 2.45 [1.95–2.95] |
| Quinolones       | 22                                              | 1.21 [0.71–1.71]                | 1415  | 38.96 [37.37–40.55] |
| Sulphonamides    | 767                                             | 42.05 [39.79–44.32]             | 1291  | 35.55 [33.99–37.10] |
| Tetracyclines    | 237                                             | 12.99 [11.45–14.54]             | 486   | 13.38 [12.27–14.49] |

Regarding TB, there were only two studies included in the analysis that investigated resistance to TB medication [74,75]. These studies reported 110 out of 499 (22.04% [95% CI: 18.41%–25.68%]) TB isolates resistant to at least one TB medication (ethambutol, isoniazid, pyrazinamide, rifampicin, and/or streptomycin). Table 4 summarizes the available data on the AMR profile for TB.
Table 4. Resistance rates against anti-Mycobacterium Tuberculosis drugs for Mycobacterium Tuberculosis.

| AMR to anti-TB drug | n  | Rate (%) | 95% CI (%) |
|---------------------|----|----------|------------|
| Ethambutol          | 33 | 6.61     | [4.43–8.79]|
| Isoniazid           | 30 | 6.01     | [3.93–8.10]|
| Pyrazinamide        | 25 | 5.01     | [3.10–6.92]|
| Rifampicin          | 25 | 5.01     | [3.10–6.92]|
| Streptomycin        | 46 | 9.22     | [6.68–11.76]|

Number of anti-TB drugs with AMR

| Monoresistance (one drug only) | 71  | 14.23 | [11.16–17.29] |
| Two drugs only                | 25  | 5.01  | [3.10–6.92]  |
| Three or more                 | 14  | 2.81  | [1.36–4.25]  |

AMR = antimicrobial resistance; TB = Mycobacterium Tuberculosis.

4. Discussion

Our research provided an up-to-date account of the literature related to AMR bacteria acquisition and transmission associated with the Hajj pilgrimage. Enteric and respiratory disease-causing, beta-lactam resistance bacteria were the most reported organisms. In this section, we discuss preventive and surveillance measures that may be adopted to reduce the risk of AMR bacteria transmission during the Hajj.

4.1. Enteric Disease-Causing Beta-Lactam Resistance Bacteria

Our literature review found that 72.27% [95% CI: 70.92%–73.63%] of the tested enteric infection-causing bacteria were resistant to beta-lactams. This was similar to what other studies have found. For instance, Santos et al. (2020) found that phenotypically 74% and genetically 94% of tested enteric samples were resistant to at least one beta-lactam antibiotic [76]. Resistance to beta-lactams expressed by enteric bacteria poses health threats that increase morbidity and mortality rates [77,78], and a mismatch between treatment and susceptibility profile leads to a worse prognosis [77,78]. Studies showed that the mortality rate ranged from 42% to 100% for patients with enteric diseases who were infected with beta-lactam-resistant bacteria but were still treated with beta-lactam antibiotics [77,78]. We recommend that physicians considering using beta-lactams to treat pilgrims and their close contacts for enteric diseases consider the AMR risk profile of these patients, and factor this into their clinical decision-making accordingly. Implementation for such recommendation can be strengthened with the availability of data and enhanced surveillance of AMR for commonly used beta-lactams and communicating recommended protocols and guidelines between health authorities related to the Hajj and destination countries.

4.2. Respiratory Disease-Causing Beta-Lactam Resistance Bacteria

Our findings show that the most common (68.58% [95% CI: 66.87%–70.29%]) AMR expressed in respiratory infection-causing bacteria was beta-lactams and that this rate was significantly higher among cases detected in Makkah. The higher detected rate of beta-lactam resistance in Makkah compared to outside Makkah could be due to the high rate of respiratory infections among the Hajj pilgrims [79] or simply the result of measurement bias. The high rate of inappropriate antibiotic prescriptions for respiratory infections in the Hajj that is reported in literature [80,81], may also have contributed to this high detected rate of beta-lactam resistance within respiratory bacteria in the Hajj. Due to the high rate of respiratory infections reported in the Hajj [79], we recommend that health authorities in the Hajj support updating and developing guidelines, that are specific for the Hajj [82], for physicians when treating Hajj pilgrims with respiratory infections.
4.2.1. AMR Isolated from Hospital Settings

We found 56.07% [95% CI: 55.06%–57.09%] of sampled bacteria collected in hospital settings in Makkah were resistant to at least one antibiotic; this is in line with the range reported elsewhere (27% to 82%) [83]. Moreover, our work found that the most common AMR bacteria was *Acinetobacter* spp. with about 88% of isolates collected resistant to at least one beta-lactam antibiotic. This is similar to a similar study’s findings [84]. Infection with *Acinetobacter* spp. is a serious health issue, as these organisms are robust and can survive in different environmental conditions, increasing the chance of antimicrobial resistance developing [85]. Therefore, hospitalized patients and pilgrims suspected to be infected with enteric bacteria, such as *Acinetobacter* spp. infections, are recommended to be tested for antimicrobial susceptibility to avoid inappropriate prescribing and thus minimise the risk of AMR development and improve treatment outcomes.

4.2.2. Surveillance of AMR Bacteria

Sixty-five percent of the studies included in our review reported AMR detection through hospital-based research. Both routine and incidental hospital and community-based surveillance are crucial to assess, predict, and follow up on the development and transmission of AMR bacteria within the Hajj [86]. Moreover, tracking the use of antibiotics (e.g., prescription and dispensing) within the Hajj event may help find foci of unwanted antibiotic usage, such as self-medication and low regimen compliance in the Hajj [86,87]. To ensure adequate surveillance mechanisms are in place to detect AMR associated with the Hajj a comprehensive strategy integrated with broader health protection planning measures are essential. A comprehensive surveillance strategy should incorporate routine hospital-based data collection, community-based surveillance (i.e., private health providers and laboratories), and active case finding when required.

4.2.3. Preventive Measures for AMR Bacteria

The prevalence of AMR transmission at the Hajj should be emphasised on prevention, early detection, and rapid response. Measures that should be considered include the development of policies that require mandatory vaccination (e.g., meningococcal) and prophylaxis before coming to Hajj; strategies to strengthen hospitals’ infection controls; the development of Hajj-specific guidelines for AMR prevention, detection and control; enhancement of hospital- and community-based surveillance for AMR; streamlining testing processes; establishment of governance arrangements that support the adoption of novel (or improved) methods of tackling AMR risk; and investing in social, clinical, and operational research to better understand transmission dynamics.

4.3. Limitations

This study has several limitations. First, most of the included studies provided limited information about participants’ demographics. Demographic data (such as age and gender) are important, as some diseases have high occurrence rates associated with specific ages. Second, we relied on the information provided in the reviewed articles and could not interrogate or validate their findings. Third, some studies were excluded as they were not available in English, which may have resulted in relevant information being missed. Forth, most studies were based on data collected as part of the research conducted in Makkah and hence, AMR detection associated with Makkah is likely overrepresented. Finally, presence of bias was not universally discussed in the manuscripts review. Existence of bias in the literature reviewed may impact the validity and generalizability of our results.

5. Conclusions

This scoping review provides a point-in-time collation of available scientific information related to AMR transmission associated with the Hajj. It provides an accessible resource for researchers and practitioners seeking insights into AMR-associated incidence and burden and identifies knowledge gaps that may be filled. Finally, the work offers
generalizable advice that those responsible for the management of AMR at mass gatherings may refer to inform their efforts.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijerph192114134/s1, S1: Search Terms; S2: Extracted data. S3: PRISMA checklist.

Author Contributions: Conceptualization, S.A.; methodology, S.A., H.B. and A.T.C.; software, S.A. and A.T.C.; validation, S.A., H.B. and A.T.C.; formal analysis, S.A.; investigation, S.A. and H.B.; resources, A.T.C.; data curation, S.A. and H.B.; writing—original draft preparation, S.A.; writing—review and editing, S.A., H.B. and A.T.C.; visualization, S.A.; supervision, A.T.C.; project administration, S.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Antimicrobial Resistance Division: National Action Plans and Monitoring and Evaluation. In Global Action Plan on Antimicrobial Resistance; World Health Organization: Geneva, Switzerland, 2015; p. 45.
2. World Health Organization. Fact Sheets: Antimicrobial Resistance. Available online: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (accessed on 16 March 2022).
3. Holmes, A.H.; Moore, L.S.; Sundsfjord, A.; Steinbakk, M.; Regmi, S.; Karkey, A.; Guerin, P.J.; Piddock, L.J. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 2016, 387, 176–187. [CrossRef]
4. Singh, V.; Chibale, K. Strategies to Combat Multi-Drug Resistance in Tuberculosis. Acc. Chem. Res. 2021, 54, 2361–2376. [CrossRef] [PubMed]
5. Murray, C.J.; Ikuta, K.S.; Sharara, F.; Aguilar, G.R.; Gray, A.; Han, C.; Bisignano, C.; Rao, P.; Wool, E. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399, 629–655. [CrossRef]
6. The Review on Antimicrobial Resistance. In Tackling Drug-Resistant Infections Globally: Final Report and Recommendations; O’Neill, J. (Ed.) Government of the United Kingdom: London, UK, 2016.
7. Frost, I.; Van Boeckel, T.P.; Pires, J.; Craig, J.; Laxminarayan, R. Global geographic trends in antimicrobial resistance: The role of international travel. J. Travel Med. 2019, 26, taz036. [CrossRef] [PubMed]
8. World Health Organization. Global Action Plan on Antimicrobial Resistance; World Health Organization: Geneva, Switzerland, 2015.
9. Bokhary, H.; Pangesti, K.N.A.; Rashid, H.; Abd El Ghany, M.; Hill-Cawthorne, G.A. Travel-Related Antimicrobial Resistance: A Systematic Review. Trop. Med. Infect. Dis. 2021, 6, 11. [CrossRef]
10. Sridhar, S.; Turbett, S.E.; Harris, J.B.; LaRocque, R.C. Antimicrobial-resistant bacteria in international travelers. Curr. Opin. Infect. Dis. 2021, 34, 423–431. [CrossRef]
11. Ahmed, Q.A.; Arabi, Y.M.; Memish, Z.A. Health risks at the Hajj. Lancet 2006, 367, 1008–1015. [CrossRef]
12. World Health Organization. Public Health for Mass Gatherings: Key Considerations; World Health Organization: Geneva, Switzerland, 2015.
13. Shafi, S.; Booy, R.; Haworth, E.; Rashid, H.; Memish, Z.A. Hajj: Health lessons for mass gatherings. J. Infect. Public Health 2008, 1, 27–32. [CrossRef]
14. Zumla, A.; McCloskey, B.; Endericks, T.; Azhar, E.I.; Petersen, E. The challenges of cholera at the 2017 Hajj pilgrimage. Lancet Infect. Dis. 2017, 17, 895–897. [CrossRef]
15. Yezli, S.; Assiri, A.M.; Alhakeem, R.F.; Turkistani, A.M.; Alotaibi, B. Meningococcal disease during the Hajj and Umrah mass gatherings. Int. J. Infect. Dis. 2016, 47, 60–64. [CrossRef]
16. Novelli, V.M.; Lewis, R.G.; Dawood, S.T. Epidemic group A meningococcal disease in Haj pilgrims. Lancet 1987, 2, 863. [CrossRef]
17. Taha, M.K.; Achtman, M.; Alonso, J.M.; Greenwood, B.; Ramsay, M.; Fox, A.; Gray, S.; Kazcmarski, E. Serogroup W135 meningococcal disease in Haj pilgrims. Lancet 2000, 356, 2159. [CrossRef]
18. Bokhary, H.; Rashid, H.; Hill-Cawthorne, G.A.; Abd El Ghany, M. The Rise of Antimicrobial Resistance in Mass Gatherings. In Handbook of Healthcare in the Arab World; Laher, I., Ed.; Springer International Publishing: Cham, Switzerland, 2020; pp. 1–16. [CrossRef]
19. Leangapichart, T.; Rolain, J.M.; Memish, Z.A.; Al-Tawfiq, J.A.; Gautret, P. Emergence of drug resistant bacteria at the Hajj: A systematic review. Travel Med. Infect. Dis. 2017, 18, 3–17. [CrossRef] [PubMed]
20. Ravi, S.J.; Meyer, D.; Cameron, E.; Nalabandian, M.; Pervaiz, B.; Nuzzo, J.B. Establishing a theoretical foundation for measuring global health security: A scoping review. BMC Public Health 2019, 19, 954. [CrossRef] [PubMed]
21. Salih, M.A.; Danielsson, D.; Backman, A.; Caugant, D.A.; Achtman, M.; Olcen, P. Characterization of epidemic and nonepidemic Neisseria meningitidis serogroup A strains from Sudan and Sweden. J. Clin. Microbiol. 1990, 28, 1711–1719. [CrossRef]
22. Willerton, L.; Lucidarme, J.; Campbell, H.; Caugant, D.A.; Claus, H.; Jacobsson, S.; Ladhani, S.N.; Molling, P.; Neri, A.; Stefanelli, P.; et al. Geographically widespread invasive meningococcal disease caused by a ciprofloxacin resistant non-groupable strain of the ST-175 clonal complex. J. Infect. 2020, 81, 575–584. [CrossRef]
23. Hazra, A. Using the confidence interval confidently. J. Thorac. Dis. 2017, 9, 4125–4130. [CrossRef]
24. Morris, J.A.; Gardner, M.J. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br. Med. J. 1988, 296, 1313–1316. [CrossRef]
25. Goodman, S. A dirty dozen: Twelve p-value misconceptions. Semin. Hematol. 2008, 45, 135–140. [CrossRef]
26. PRISMA Statement. PRISMA Flow Diagram. Available online: http://www.prisma-statement.org/PRISMAStatement/FlowDiagram (accessed on 15 March 2022).
27. Asghar, A.H. Frequency and antimicrobial susceptibility patterns of bacterial pathogens isolated from septicemic patients in Makkah hospitals. Saudi Med. J. 2006, 27, 361–367.
28. Asghar, A.H.; Momenah, A.M. Methicillin resistance among Staphylococcus aureus isolates from Saudi hospitals. Med. Princ. Pract. 2006, 15, 52–55. [CrossRef] [PubMed]
29. Karima, T.M.; Bukhari, S.Z.; Ghais, M.A.; Fatani, M.I.; Hussain, W.M. Prevalence of Helicobacter pylori infection in patients with peptic ulcer diseases. Saudi Med. J. 2006, 27, 621–626. [PubMed]
30. Memish, Z.A.; Balkhy, H.H.; Almuneef, M.A.; Al-Haj-Hussein, B.T.; Bukhari, A.I.; Osoba, A.O. Carriage of Staphylococcus aureus among Hajj pilgrims. Saudi Med. J. 2006, 27, 1367–1372. [PubMed]
31. Asghar, A.H. Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from 2 hospitals in Makkah, Saudi Arabia. Saudi Med. J. 2006, 27, 1017–1023.
32. Asghar, A.H.; Faidah, H.S. Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from 2 hospitals in Makkah, Saudi Arabia. Ann. Saudi Med. 2011, 31, 462–468. [CrossRef]
33. El-Amin, N.M.; Faidah, H.S. Vancomycin-resistant Enterococci. Prevalence and risk factors for fecal carriage in patients at tertiary care hospitals. Saudi Med. J. 2011, 32, 966–967.
34. Asghar, A.H. Antimicrobial susceptibility and metallo-beta-lactamase production among Pseudomonas aeruginosa isolated from Makkah hospitals. Pak. J. Med. Sci. 2012, 28, 7.
35. Asghar, A.H. Molecular characterization of mecillinm-resistant Staphylococcus aureus isolated from tertiary care hospitals. Pak. J. Med. Sci. 2014, 30, 698–702. [CrossRef]
36. Khan, M.M.; Faiz, A.; Ashshi, A.M. Clinically significant Coagulase Negative Staphylococci and their antibiotic resistance pattern in a tertiary care hospital. J. Pak. Med. Assoc. 2014, 64, 1171–1174.
37. Abdel-Haleem, A.M.; Rchiad, Z.; Khan, B.K.; Abdallah, A.M.; Naeem, R.; Nikhat Sheerin, S.; Solovyev, V.; Ahmed, A.; Pain, A. Genome Sequence of a Multidrug-Resistant Strain of Stenotrophomonas maltophilia with Carbapenem Resistance, Isolated from King Abdullah Medical City, Makkah, Saudi Arabia. Genome Announc. 2015, 3, e00375-16. [CrossRef] [PubMed]
38. Alyamani, E.J.; Khiyami, A.M.; Booq, R.Y.; Alnafaji, B.M.; Altammami, M.A.; Bahwerther, F.S. Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of Acinetobacter baumannii in Saudi Arabia. Ann. Clin. Microbiol. Antimicrob. 2015, 14, 38. [CrossRef] [PubMed]
39. Algowaihi, R.; Ashgar, S.; Sirag, B.; Shalam, S.; Nassir, A.; Ahmed, A. Draft Genome Sequence of a Multidrug-Resistant Klebsiella pneumoniae Strain Isolated from King Abdullah Medical City, Makkah, Saudi Arabia. Genome Announc. 2016, 4, e00375-16. [CrossRef] [PubMed]
40. Alyamani, E.J.; Khiyami, A.M.; Booq, R.Y.; Bahwerther, F.S.; Vaisvil, B.; Schmitt, D.P.; Kapatral, V. Genome sequence and comparative pathogenic determinants of multidrug resistant uropathogenic Escherichia coli 025b:h4, a clinical isolate from Saudi Arabia. J. Pure Appl. Microbiol. 2016, 10, 2475–2484. [CrossRef]
41. Haseeb, A.; Faidah, H.S.; Baksh, A.R.; Malik, W.H.; Elrggal, M.E.; Saleem, F.; Rahman, S.U.; Khan, T.M.; Hassali, M.A. Antimicrobial resistance among pilgrims: A retrospective study from two hospitals in Makkah, Saudi Arabia. Int. J. Infect. Dis. 2016, 47, 92–94. [CrossRef]
42. Johargy, A.K. Antimicrobial susceptibility of bacterial and fungal infections among infected diabetic patients. J. Pak. Med. Assoc. 2016, 66, 1291–1295. [PubMed]
43. Khan, M.A.; Faiz, A. Antimicrobial resistance patterns of Pseudomonas aeruginosa in tertiary care hospitals of Makkah and Jeddah. Ann. Saudi Med. 2016, 36, 23–28. [CrossRef]
44. Al-Gethamy, M.M.; Faidah, H.S.; Adetunji, H.A.; Haseeb, A.; Ashgar, S.S.; Mohammed, T.K.; Mohammed, A.H.; Khurram, M.; Hassali, M.A. Risk factors associated with multi-drug-resistant Acinetobacter baumannii nosocomial infections at a tertiary care hospital in Makkah, Saudi Arabia—A matched case-control study. J. Int Med. Res. 2017, 45, 1181–1189. [CrossRef]
46. Alyamani, E.J.; Khayami, A.M.; Boog, R.Y.; Majrashi, M.A.; Bahwerth, F.S.; Rechkind, E. The occurrence of ESBL-producing Escherichia coli carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia. *Ann. Clin. Microbiol. Antimicrob.* **2017**, *16*, 1. [CrossRef]

47. Khan, M.A.; Mohamed, A.M.; Faiz, A.; Ahmad, J. Enterobacterial infection in Saudi Arabia: First record of Klebsiella pneumoniae with triple carbapenemase genes resistance. *J. Infect. Dev. Cities* **2019**, *13*, 334–341. [CrossRef]

48. Mater, M.E.; Yamani, A.E.; Aljuffri, A.A.; Binladen, S.A. Epidemiology of burn-related infections in the largest burn unit in Saudi Arabia. *Saudi Med. J.* **2020**, *41*, 726–732. [CrossRef] [PubMed]

49. Ahmed, O.B.; Asghar, A.H.; Bahwerth, F.S. Increasing frequency of Aminoglycoside-Resistant Klebsiella pneumoniae during the era of pandemic COVID-19. *Mater. Today Proc.* **2021**, in press. [CrossRef] [PubMed]

50. Ahmed, O.B.; Asghar, A.H.; Bahwerth, F.S.; Assaggaf, H.M.; Bamaga, M.A. The prevalence of aminoglycoside-resistant genes in Gram-negative bacteria in tertiary hospitals. *Appl. Nanosci.* **2021**, [CrossRef]

51. Al-Zahrani, I.A.; Al-Ahmadi, B.M. Dissemination of VIM-producing Pseudomonas aeruginosa associated with high-risk clone ST654 in a tertiary and quaternary hospital in Makkah, Saudi Arabia. *J. Chemother.* **2021**, *33*, 12–20. [CrossRef] [PubMed]

52. Haseeb, A.; Faidah, H.S.; Algethami, M.; Alghamdy, S.; Alhazmi, G.A.; Alshomrani, A.O.; Alqethami, B.R.; Alotibi, H.S.; Almutiri, M.Z.; Almuqati, K.S.; et al. Antimicrobial Usage and Resistance in Makkah Region Hospitals: A Regional Point Prevalence Survey of Public Hospitals. *Int. J. Environ. Res. Public Health* **2022**, *19*, 254. [CrossRef]

53. Ng, P.P.; Taha, M. Tetracycline resistant Vibrio cholerae in pilgrims returning from Mecca. *Med. J. Malays.* **1994**, *49*, 195.

54. Yousuf, M.; Nadeem, A. Fatal meningococcal meningitis due to group W135 amongst Haj pilgrims: Implications for future vaccination policy. *Ann. Trop. Med. Parasitol.* **1995**, *89*, 321–322. [CrossRef]

55. Ahmed Khan, T.; Sheikh, M.; Azher, I.; Sheikh, A.K. Burn aggravated infected wart in a patient with type 2 diabetes: A medical challenge. *BMJ Case Rep.* **2018**, bcr-2017-222897. [CrossRef]

56. Leangapichart, T.; Hadjadj, L.; Gautret, P.; Rolain, J.M. Comparative genomics of two Shewanella xiamenensis isolates isolated from a pilgrim before and during travels to the Hajj. *Gut Pathog.* **2021**, *13*, 9. [CrossRef]

57. Turkstani, M.A.; Sultan, R.M.S.; Al-Hindi, R.R.; Ahmed, M.M.M. Molecular identification of microbial contaminations in the fitness center in Makkah region. *Biosci. J.* **2021**, *37*, e37020. [CrossRef]

58. Leangapichart, T.; Dia, N.M.; Olaitan, A.O.; Gautret, P.G.; Brouqui, P.; Rolain, J.M. Acquisition of Extended-Spectrum beta-Lactamases by Escherichia coli and Klebsiella pneumoniae in Gut Microbiota of Pilgrims during the Hajj Pilgrimage of 2013. *Antimicrob. Agents Chemother.* **2016**, *60*, 3222–3226. [CrossRef] [PubMed]

59. Leangapichart, T.; Gautret, P.; Brouqui, P.; Mimish, Z.; Raoult, D.; Rolain, J.M. Acquisition of mcr-1 plasmid-mediated colistin resistance in Escherichia coli and Klebsiella pneumoniae during Hajj 2013 and 2014. *Antimicrob. Agents Chemother.* **2016**, *60*, 6998–6999. [CrossRef] [PubMed]

60. Leangapichart, T.; Gautret, P.; Griffiths, K.; Belhouchat, K.; Memish, Z.; Raoult, D.; Rolain, J.M. Acquisition of a High Diversity of Bacteria during the Hajj Pilgrimage, Including Acinetobacter baumannii with blaOXA-72 and Escherichia coli with blaNDM-5 Carbapenemase Genes. *Antimicrob. Agents Chemother.* **2016**, *60*, 5942–5948. [CrossRef] [PubMed]

61. Marghalani, A.A.; Madani, T.A. Acute rhinosinusitis during Hajj season 2014: Prevalence of bacterial infection and patterns of antibiotic susceptibility. *Travel Med. Infect. Dis.* **2016**, *14*, 583–587. [CrossRef] [PubMed]

62. Abd El Ghany, M.; Alsomali, M.; Almasri, M.; Padron Regalado, E.; Naeem, R.; Tukestani, A.; Asiri, A.; Hill-Cawthorne, G.A.; Pain, A.; Memish, Z.A. Enteric Infections Circulating during Hajj Seasons, 2011-2013. *Emerg. Infect. Dis.* **2017**, *23*, 1640–1649. [CrossRef]

63. Alghamdi, S. Microbiological profile and antibiotic vulnerability of bacterial isolates from cancer patients. *Cell. Mol. Biol.* **2021**, *67*, 190–194. [CrossRef]

64. Hoang, V.T.; Dao, T.L.; Ly, T.D.A.; Gouriet, F.; Hadjadj, L.; Belhouchat, K.; Chaht, K.L.; Yezli, S.; Alotaibi, B.; Raoult, D.; et al. Acquisition of multidrug-resistant bacteria and encoding genes among French pilgrims during the 2017 and 2018 Hajj. *Eur. J. Clin. Microbiol. Infect. Dis.* **2021**, *40*, 1199–1209. [CrossRef]

65. Mohd Baharin, I.E.; Hasan, H.; Nik Mohd Noor, N.Z.; Mohamed, M. Molecular detection of selected zoonotic respiratory pathogens and the presence of virulence and antibiotic resistance genes via PCR among Kelantan Hajj pilgrims. *Malays. J. Microbiol.* **2021**, *17*, 254–265. [CrossRef]

66. Olaitan, A.O.; Dia, N.M.; Gautret, P.; Benkouiten, S.; Belhouchat, K.; Drali, T.; Parola, P.; Brouqui, P.; Memish, Z.; Raoult, D.; et al. Acquisition of extended-spectrum cephalosporin- and colistin-resistant Salmonella enterica subsp. enterica serotype Newport by pilgrims during Hajj. *Int. J. Antimicrob. Agents* **2015**, *45*, 600–604. [CrossRef]

67. Fatani, M.I.; Bukhari, S.Z.; Al-Arif, K.A.; Karima, T.M.; Abdulghani, M.R.; Al-Kaltham, M.I. Pyoderma among Hajj Pilgrims in Makkah. *Saudi Med. J.* **2002**, *23*, 782–785.

68. Abulreesh, H.H.; Organji, S.R.; Osman, G.E.H.; Elbanna, K.; Almalki, M.H.K.; Ahmad, I. Prevalence of antibiotic resistance and virulence factors encoding genes in clinical Staphylococcus aureus isolates in Saudi Arabia. *Clin. Epidemiol. Glob. Health* **2017**, *5*, 196–202. [CrossRef]

69. Abulreesh, H.H.; Organji, S.R. The Prevalence of Multidrug-resistant Staphylococci in Food and the Environment of Makkah, Saudi Arabia. *Res. J. Microbiol.* **2011**, *6*, 510–523. [CrossRef]
